Log in

Relevant bibliographies by topics / Lafutidine / Journal articles

To see the other types of publications on this topic, follow the link: Lafutidine.

Journal articles on the topic 'Lafutidine'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Lafutidine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Damodhar, Vijay Kumar. "Formulation and Evaluation of Floating in Situ Gel of Lafutidine." International Journal of Medical, Pharmacy and Drug Research 7, no. 5 (2023): 08–14. http://dx.doi.org/10.22161/ijmpd.7.5.2.

Full text

Abstract:

Gastroesophageal reflux disease (GERD) and peptic ulcers are prevalent gastrointestinal disorders that significantly impact the quality of life of affected individuals. Lafutidine, a histamine H2-receptor antagonist, has demonstrated effectiveness in managing these conditions. However, its short gastric residence time limits its therapeutic efficacy. To address this limitation, we aimed to formulate and evaluate a floating in situ gel of Lafutidine for prolonged gastric retention and enhanced therapeutic outcomes. In vivo studies were conducted on albino Wistar rats to assess the pharmacokinet

APA, Harvard, Vancouver, ISO, and other styles

2

Kumar, Ritesh, Amrish Chandra, Swati Gupta, and Pawan Kumar Gautam. "DEVELOPMENT AND VALIDATION OF UV SPECTROPHOTOMETRIC METHOD FOR QUANTITATIVE ESTIMATION OF LAFUTIDINE IN BULK AND PHARMACEUTICAL DOSAGE FORM." International Journal of Applied Pharmaceutics 9, no. 6 (2017): 75. http://dx.doi.org/10.22159/ijap.2017v9i6.21943.

Full text

Abstract:

Objective: The objectives of the present research was to develop a simple, precise, economical, accurate, reproducible and sensitive method for the quantitative estimation of lafutidine in bulk and its pharmaceutical dosage forms by Ultra Violet (UV) absorption spectrophotometry.Methods: The method uses 0.1 N HCl, pH 1.20 as a solvent of choice for the quantitative estimation of lafutidine in bulk and its tablets dosage form by UV absorption spectrophotometry at a wavelength of 290 nm. The method was validated for parameters like linearity, range, precision, Limit of Detection (LOD), Limit of

APA, Harvard, Vancouver, ISO, and other styles

3

Deshmukh, Mr Vikram Tanaji, and Dr Jagdish Chandra Pati. "Development and Evaluation of In-Situ Floating Gel In treatment of Gastroesophageal Reflux Disease (Gerd)." Journal of Drug Discovery and Therapeutics 11, no. 2 (2023): 70–92. http://dx.doi.org/10.32553/jddt.v11i2.466.

Full text

Abstract:

Gastroretentive drug delivery systems can deliver narrow-window drugs to the upper stomach at a controlled rate. The raft forming process is better than floating structures, liquid dosing mediums, and in situ gelation for sustained drug release in the upper GI tract. According to statistics, lafutidine is exactly put in the parietal cells of the stomach mucosa, where the upper gastro-intestinal tract absorbs it. Lafutidine capsules had 65–70% bioavailability compared to intravenous infusion. Stability and absorption are acceptable between 1 and 4. The colon and lower gastrointestinal tract deg

APA, Harvard, Vancouver, ISO, and other styles

4

Dewan, Bhupesh, and Nisha Philipose. "Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial." Gastroenterology Research and Practice 2011 (2011): 1–8. http://dx.doi.org/10.1155/2011/640685.

Full text

Abstract:

Background. Empirical therapy with antisecretory agents like PPIs and H2RAs has long been the traditional approach in the initial management of uninvestigated dyspepsia.Aim. The objective of the study was to examine relief of dyspepsia with lafutidine, a second-generationH2-RA, and rabeprazole and to compare their efficacy.Methods. This was a randomized, open, comparative trial in adult uninvestigated dyspeptic patients, who had at least moderate severity of symptoms, defined as a score of≥4 on a 7-point global overall symptom (GOS) scale, and were randomized to receive once daily either lafut

APA, Harvard, Vancouver, ISO, and other styles

5

Deshmukh, Mr Vikram Tanaji, and Dr Jagdish Chandra Pati. "Development and Validation of RP-HPLC Method of Lafutidine (API)." Journal of Drug Discovery and Therapeutics 11, no. 2 (2023): 93–104. http://dx.doi.org/10.32553/jddt.v11i2.467.

Full text

Abstract:

The goal of this study is to develop and validate an RP HPLC technique for estimating Lafutidine in bulk form. A thorough review of the literature found that there are ways available, but none of them are as straightforward, specific, exact, or accurate as the established approach for estimating Lafutidine. The chromatographic method was found to be suitable for effective separation of Lafutidine with good resolution, peak shape. The mobile phase composed of 0.1M ammonium acetate buffer (pH 7.5): Methanol (80:20 v/v), at a flow rate of 1.4 ml/min was selected as it gave well resolved peaks of

APA, Harvard, Vancouver, ISO, and other styles

6

Rahul, Kumar Garg, and Singhvi Indrajeet. "DEVELOPMENT AND VALIDATION OF UV SPECTROPHOTOMETRIC METHOD FOR QUANTITATIVE ESTIMATION OF LAFUTIDINE FROM TABLET FORMULATION." Pharmaceutical and Chemical Journal 1, no. 2 (2014): 1–4. https://doi.org/10.5281/zenodo.13690955.

Full text

Abstract:

One simple and sensitive spectrophotometric method has been developed for the quantitative estimation of Lafutidine from tablet. The method was developed and based on the solubility of Lafutidine in 0.1 N HCl (pH 1.2). The drug showed maximum absorbance at 286 nm and linearity (Lambert Beer’s Range) was found in concentration range of 10-60 μg/ml and the standard curve equation was found to be  y = 0.015x - 0.015 and R<sup>2</sup> value 0.997. The results of analysis were validated statistically and by recovery studies. The result of analysis was validated as per ICH guidelines a

APA, Harvard, Vancouver, ISO, and other styles

7

Jadhav, Kiran, D. L. Dhamecha, S. V. Ghadlinge, G. P. Asnani, and M. B. Patil. "Simultaneous Estimation of Lafutidine and Domperidone by Ultraviolet Spectroscopy." ISRN Analytical Chemistry 2012 (June 21, 2012): 1–4. http://dx.doi.org/10.5402/2012/401702.

Full text

Abstract:

A simple, accurate, and precise method for simultaneous estimation of Lafutidine and Domperidone in combined-dosage form have been described. The method employs formation and solving of simultaneous equations using 279 and 284 nm as two analytical wavelengths. This method allows the simultaneous determination of Lafutidine and Domperidone in concentration ranges employed for this purpose with the standard deviation of <1.0% in the assay of tablet.

APA, Harvard, Vancouver, ISO, and other styles

8

Sanjivani Gorakhnath Borkar, Lahu Hingane, Parvati. D. Shere, and Vilas Ingole. "Development and validation of RP-HPLC method for the simultaneous estimation of rabeprazole sodium and lafutidine in combined dosage form." World Journal of Biology Pharmacy and Health Sciences 14, no. 2 (2023): 240–50. http://dx.doi.org/10.30574/wjbphs.2023.14.2.0200.

Full text

Abstract:

A simple, rapid, specific, accurate and precise RP-HPLC method was developed for the simultaneous estimation of Lafutidine and Rabeprazole Sodium in combined dosage form. A Hi Q sil C-8 Column (250 mm × 4.6 mm, 5 μm) in Isocratic mode with mobile phase containing Acetonitrile : Phosphate Buffer (70:30 v/v) pH 7.3 was used. The flow rate was 1.0ml/min and effluents were monitored at 230 nm. The retention time of Rabeprazole Sodium and Lafutidine was found to be 3.658 min and 5.408 min respectively. Validation parameters such as linearity, precision, accuracy, limit of detection(LOD), limit of q

APA, Harvard, Vancouver, ISO, and other styles

9

Sanjivani, Gorakhnath Borkar, Hingane Lahu, D. Shere Parvati., and Ingole Vilas. "Development and validation of RP-HPLC method for the simultaneous estimation of rabeprazole sodium and lafutidine in combined dosage form." World Journal of Biology Pharmacy and Health Sciences 14, no. 2 (2023): 240–50. https://doi.org/10.5281/zenodo.8039203.

Full text

Abstract:

A simple, rapid, specific, accurate and precise RP-HPLC method was developed for the simultaneous estimation of Lafutidine and Rabeprazole Sodium in combined dosage form. A Hi Q sil C-8 Column (250 mm × 4.6 mm, 5 μm) in Isocratic mode with mobile phase containing Acetonitrile : Phosphate Buffer (70:30 v/v) pH 7.3 was used. The flow rate was 1.0ml/min and effluents were monitored at 230 nm. The retention time of Rabeprazole Sodium and Lafutidine was found to be 3.658 min and 5.408 min respectively. Validation parameters such as linearity, precision, accuracy, limit of detection(LOD), l

APA, Harvard, Vancouver, ISO, and other styles

10

Machida, Nozomu, Masanori Terashima, Keisei Taku, et al. "A prospective multicenter trial of S-1 with lafutidine vs S-1 as adjuvant chemotherapy for gastric cancer in Japan: AEOLUS." Journal of Clinical Oncology 36, no. 4_suppl (2018): 91. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.91.

Full text

Abstract:

91 Background: From the result of ACTS-GC study, adjuvant chemotherapy with S-1 for one year is standard therapy of gastric cancer in Japan. In this study, completion rate of pre-planned S-1 treatment was 65.8% and there is still room for improvement on this rate. Lafutidine is a H2 blocker and enhances submucosal blood flow via capsaicin-sensitive afferent neurons. Alleviating effect of lafutidine on toxicity of 5FU leading to discontinuation of adjuvant treatment could be expected. Methods: Patients with histologically confirmed stage II (excluding T1 cases), IIIA, or IIIB (Japanese Classifi

APA, Harvard, Vancouver, ISO, and other styles

11

Sapate, K. A., P. V. Dangre, and M. D. Godbole. "FORMULATION AND STATISTICAL OPTIMIZATION OF MULTIPARTICULATE LAFUTIDINE-LOADED GASTRORETENTIVE DELIVERY SYSTEM USING 32- FACTORIAL DESIGN." INDIAN DRUGS 51, no. 10 (2014): 43–54. http://dx.doi.org/10.53879/id.51.10.10169.

Full text

Abstract:

The purpose of this research was to develop and optimize buoyant beads containing lafutidine by ionic-gelation method for gastroretentive delivery. The effect of two independent process variables like NaHCO 3: Polymer, Drug: Polymer ratio on % drug entrapment, % swelling and % drug release of buoyant beads containing lafutidine was optimized using 32 factorial designs. The observed responses coincided well with the predicted values, given by the optimization technique. The optimized beads showed drug entrapment efficiency 78.76+0.27%, swelling 69.90+0.13%, cumulative drug release 69.00+0.36% a

APA, Harvard, Vancouver, ISO, and other styles

12

Pravinchandra, Shah Kinalkumar, Moolchand Kurmi, Sanjay Kumar, and Saranjit Singh. "Forced degradation of lafutidine and characterization of its non-volatile and volatile degradation products using LC-MS/TOF, LC-MSn and HS-GC-MS." New Journal of Chemistry 39, no. 12 (2015): 9679–92. http://dx.doi.org/10.1039/c5nj02096d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Dolas, Ramdas T., Shalindra Sharma, and Madhuraj Sharma. "FORMULATION AND EVALUATION OF GASTRORETENTIVE FLOATING TABLETS OF LAFUTIDINE." Journal of Drug Delivery and Therapeutics 8, no. 5 (2018): 393–99. http://dx.doi.org/10.22270/jddt.v8i5.1898.

Full text

Abstract:

The purpose of this research was to develop a novel gastroretentive drug delivery system based on wet granulation technique for sustained delivery of active agent. Quick GI transit could result in incomplete drug release from the drug delivery system above the absorption zone leading to decreased efficacy of the administered dose and thus less patient compliance. Gastroretentive floating tablets, which was designed to provide the desired sustained and complete release of drug for prolonged period of time. Gastroretentive floating tablets of lafutidine were prepared by wet granulation technique

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Lafutidine strengthens the mucus barrier,." Inpharma Weekly &NA;, no. 1616 (2007): 23. http://dx.doi.org/10.2165/00128413-200716160-00052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Prous, J., A. Graul, and J. Castañer. "Lafutidine < Prop INN >." Drugs of the Future 19, no. 9 (1994): 835. http://dx.doi.org/10.1358/dof.1994.019.09.263047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Yamamoto, Hajime, Kazuhiko Ishihara, Yuko Takeda, Wasaburo Koizumi, and Takafumi Ichikawa. "Changes in the Mucus Barrier during Cisplatin-Induced Intestinal Mucositis in Rats." BioMed Research International 2013 (2013): 1–8. http://dx.doi.org/10.1155/2013/276186.

Full text

Abstract:

Aim. Gastrointestinal mucositis is a frequent complication of antineoplastic chemotherapy, but the effects of chemotherapy on mucosal defense mechanisms remain poorly understood. We studied the effects of cisplatin on mucin, one of the principal defense factors of the gastrointestinal mucosa, and evaluated the efficacy of two different types of H2-receptor antagonists against cisplatin-induced mucositis.Methods. Cisplatin (6 mg/kg) was administered intravenously to rats (day 0). The rats were sacrificed 1, 3, 7, and 11 days after treatment, and their stomach, jejunum, ileum, and colon were rem

APA, Harvard, Vancouver, ISO, and other styles

17

Tsujimoto, Tatsuhiro, Hiroi Iioka, Tadashi Namisaki, et al. "A Case of Anaphylaxis Induced by Lafutidine." Nihon Kyukyu Igakukai Zasshi 13, no. 7 (2002): 385–88. http://dx.doi.org/10.3893/jjaam.13.385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Dawood, Noor Mohammed, Shaimaa Nazar Abdal-hammid, and Ahmed Abbas Hussien. "FORMULATION AND CHARACTERIZATION OF LAFUTIDINE NANOSUSPENSION FOR ORAL DRUG DELIVERY SYSTEM." International Journal of Applied Pharmaceutics 10, no. 2 (2018): 20. http://dx.doi.org/10.22159/ijap.2018v10i2.23075.

Full text

Abstract:

Objective: The objective of this study was to prepare nanosuspension of a practical water insoluble antiulcer drug which is lafutidine to enhance the solubility, dissolution rate with studying the effect of different formulation variables to obtain the best formula with appropriate physical properties and higher dissolution rate.Methods: Nanosuspension of lafutidine was prepared using solvent anti-solvent precipitation method using Polyvinylpyrrolidone K-90(PVP K-90) as the stabilizer. Ten formulations were prepared to show the effect of different variables in which two formulations showed the

APA, Harvard, Vancouver, ISO, and other styles

19

Sarfaraz Md, Sarfaraz Md, Irfan Alam Shabbir Khan, and H. Doddayya H. Doddayya. "“Design and Characterization of Porous Floating Beads of Lafutidine”." Journal of Research in Pharmaceutical Science 10, no. 11 (2024): 15–17. https://doi.org/10.35629/2995-10110517.

Full text

Abstract:

The aim of present research work was to design and characterize porous floating beads of lafutidine a second-generation H2–receptor antagonist. Using the emulsion gelation method, Lafutidine porous floating beads were meticulously crafted, incorporating hydrophilic polymers such as sodium alginate (serving as the gelling agent), along with hydroxypropyl methylcellulose K15M, hydroxypropyl methylcellulose K4M and Carbopol 934p as polymers. Calcium carbonate was introduced as the gas-generating agent, while calcium chloride played the crucial role of the cross-linking agent. The effect of differ

APA, Harvard, Vancouver, ISO, and other styles

20

Furuhashi, Mitsuyoshi, and Mitsuyoshi Nakashima. "Pharmacokinetic study of lafutidine in patients under hemodialysis." Nihon Toseki Igakkai Zasshi 35, no. 1 (2002): 35–42. http://dx.doi.org/10.4009/jsdt.35.35.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Toida, M., K. Kato, H. Makita, et al. "Palliative effect of lafutidine on oral burning sensation." Journal of Oral Pathology & Medicine 38, no. 3 (2009): 262–68. http://dx.doi.org/10.1111/j.1600-0714.2008.00736.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Curtis, Howard S., John I. Jones, Nick J. Wight, et al. "Lafutidine, a novel H2-antagonist, prevents aspirin-induced dyspepsia." Gastroenterology 118, no. 4 (2000): A1224—A1225. http://dx.doi.org/10.1016/s0016-5085(00)80733-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Wu, Chengjun, Zhen Li, Chunchao Wang, Yanan Zhou, and Tiemin Sun. "Increasing the Purity of Lafutidine Using a “Suicide Substrate”." Organic Process Research & Development 22, no. 9 (2018): 1081–85. http://dx.doi.org/10.1021/acs.oprd.8b00070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

KANEKO, HIROSHI. "Dual effect of lafutidine on the gut and liver." Journal of Gastroenterology and Hepatology 18, no. 3 (2003): 237–38. http://dx.doi.org/10.1046/j.1440-1746.2003.02986.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

M, Sindhoor S., Sneh Priya, and Amala Maxwell. "FORMULATION AND EVALUATION OF NOVEL IN SITU GEL OF LAFUTIDINE FOR GASTRO RETENTIVE DRUG DELIVERY." Asian Journal of Pharmaceutical and Clinical Research 11, no. 8 (2018): 88. http://dx.doi.org/10.22159/ajpcr.2018.v11i8.25582.

Full text

Abstract:

Objective: The aim of the present study was to formulate and evaluate the novel in situ gel of lafutidine for gastroretentive drug deliveryMethods: A gastroretentive in situ gel of lafutidine was formulated by pH-triggered ionic gelation method using different concentrations of gelling polymer such as sodium alginate, gellan gum, and xanthum gum. Prepared formulations were evaluated for viscosity, density, buoyancy lag time and buoyancy duration, and drug content. In vitro drug release studies of all formulations were also performed. In vivo fluorescence imaging study was conducted for optimiz

APA, Harvard, Vancouver, ISO, and other styles

26

Yun, Jieun. "Prescription of Gastric Acid Secretion Inhibitors before and after the Withdrawal of Ranitidine." Korean Journal of Health Promotion 22, no. 4 (2022): 183–93. http://dx.doi.org/10.15384/kjhp.2022.22.4.183.

Full text

Abstract:

Background: In September 2019, ranitidine, the largest share in the gastric acid secretion inhibitor market, was identified as a carcinogen, and sales were banned. The purpose of this study was to investigate how the gastric acid secretion inhibitor market changed after ranitidine withdrawal.Methods: From January 2010 to December 2021, the prescription dose and cost of gastric acid secretion inhibitors were calculated monthly. To investigate the effect of ranitidine withdrawal on the gastric acid secretion inhibitor market, we developed a time-series autoregressive model using data from Januar

APA, Harvard, Vancouver, ISO, and other styles

27

Murata, Takahiko, Masahiro Kawashima, and Yasuo Terayama. "Patient with Central Nervous System Side Effects due to Lafutidine." Nihon Naika Gakkai Zasshi 101, no. 7 (2012): 2048–50. http://dx.doi.org/10.2169/naika.101.2048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Parmar, Komal, and Nitisha Yagneshwari. "Gastroretentive Chronopharmaceutical Formulation of Lafutidine for Early Morning Acid Breakthrough." Pharmacophore 13, no. 5 (2022): 1–7. http://dx.doi.org/10.51847/kwfmn53pu5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Kaur, Loveleen, Ajay Kumar Thakur, Pradeep Kumar, and Inderbir Singh. "Synthesis and characterization of Chitosan-Catechol conjugates: Development and in vitro, in silico and in vivo evaluation of mucoadhesive pellets of lafutidine." Journal of Bioactive and Compatible Polymers 36, no. 2 (2021): 139–51. http://dx.doi.org/10.1177/0883911521997849.

Full text

Abstract:

Present study was aimed to synthesize and characterize Chitosan-Catechol conjugates and to design and develop mucoadhesive pellets loaded with lafutidine. SEM images indicated the presence of fibrous structures responsible for enhanced mucoadhesive potential of Chitosan-Catechol conjugates. Thermodynamic stability and amorphous nature of conjugates was confirmed by DSC and XRD studies respectively. Rheological studies were used to evaluate polymer mucin interactions wherein strong interactions between Chitosan-Catechol conjugate and mucin was observed in comparison to pristine chitosan and muc

APA, Harvard, Vancouver, ISO, and other styles

30

Raghavendra Rao, N. G., and Amrita Bisht. "Formulation and Evaluation of Lafutidine Gas Powered System for Controlled Release." International Journal of Pharmaceutical Sciences Review and Research 66, no. 1 (2021): 119–25. http://dx.doi.org/10.47583/ijpsrr.2021.v66i01.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Patil, Satish, and Gokul S. Talele. "Gastroretentive mucoadhesive tablet of lafutidine for controlled release and enhanced bioavailability." Drug Delivery 22, no. 3 (2014): 312–19. http://dx.doi.org/10.3109/10717544.2013.877099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Jadhav, Kiran V., Dinesh L. Dhamecha, Geet P. Asnani, Pranali R. Patil, and Mrityunjaya B. Patil. "Stability-indicating stress degradation studies of lafutidine using UV spectrophotometric method." Pharmaceutical Methods 4, no. 1 (2013): 21–25. http://dx.doi.org/10.1016/j.phme.2013.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Jabir, Saba Abdulhadee, and Halah Talal Sulaiman. "PREPARATION AND CHARACTERIZATION OF LAFUTIDINE AS IMMEDIATE RELEASE ORAL STRIP USING DIFFERENT TYPE OF WATER-SOLUBLE POLYMER." International Journal of Applied Pharmaceutics 10, no. 5 (2018): 249. http://dx.doi.org/10.22159/ijap.2018v10i5.28292.

Full text

Abstract:

Objective: The objective of the present study was to design and optimize oral fast dissolving film (OFDF) of practically insoluble drug lafutidine in order to enhance bioavailability and patient compliance especially for a geriatric and unconscious patient who are suffering from difficulty in swallowing.Methods: The films were prepared by a solvent casting method using low-grade hydroxyl propyl methyl cellulose (HPMC E5), polyvinyl alcohol (PVA), and sodium carboxymethyl cellulose (SCMC) as film forming polymers. Polyethylene glycol 400 (PEG400), propylene glycol (PG) and glycerin were used as

APA, Harvard, Vancouver, ISO, and other styles

34

Hazra, Avijit, AmalKanti Das, Somnath Maity, and Supriyo Choudhury. "Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia." Indian Journal of Pharmacology 46, no. 5 (2014): 498. http://dx.doi.org/10.4103/0253-7613.140580.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Dhamecha, Dinesh, Ritesh Fule, Shyam Ghadlinge, Kiran Jadhav, and Santosh Shelke. "Development and validation of a stability indicating HPTLC-densitometric method for lafutidine." Chronicles of Young Scientists 4, no. 2 (2013): 108. http://dx.doi.org/10.4103/2229-5186.115549.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Harada, Keiko, Sumio Hirata, Yoshiko Okuhira, et al. "Two hemodialysis patients with central nervous system side effects due to lafutidine." Nihon Toseki Igakkai Zasshi 38, no. 3 (2005): 213–17. http://dx.doi.org/10.4009/jsdt.38.213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kunieda, Kana, Akiyoshi Someya, Syunji Horie, Hirofusa Ajioka, and Toshihiko Murayama. "Lafutidine-Induced Increase in Intracellular Ca2+ Concentrations in PC12 and Endothelial Cells." Journal of Pharmacological Sciences 97, no. 1 (2005): 67–74. http://dx.doi.org/10.1254/jphs.fpj04042x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Mikawa, Katsuya, Kahoru Nishina, Takanobu Uesugi, Makoto Shiga, and Hidefumi Obara. "Lafutidine vs cimetidine to decrease gastric fluid acidity and volume in children." Canadian Journal of Anesthesia/Journal canadien d'anesthésie 50, no. 4 (2003): 425–26. http://dx.doi.org/10.1007/bf03021049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Akiba, Yasutada, and Jonathan D. Kaunitz. "Lafutidine, a Protective H2 Receptor Antagonist, Enhances Mucosal Defense in Rat Esophagus." Digestive Diseases and Sciences 55, no. 11 (2010): 3063–69. http://dx.doi.org/10.1007/s10620-010-1379-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

NOZAWA, YOSHIHISA, KATSUSHI NISHIHARA, YUSHIRO AKIZAWA, et al. "Lafutidine inhibits Helicobacter pylori-induced interleukin-8 production in human gastric epithelial cells." Journal of Gastroenterology and Hepatology 19, no. 5 (2004): 506–11. http://dx.doi.org/10.1111/j.1440-1746.2003.03330.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Nishihara, Katsushi, Yoshihisa Nozawa, Motoko Nakano, Hirofusa Ajioka, and Naosuke Matsuura. "Sensitizing effects of lafutidine on CGRP-containing afferent nerves in the rat stomach." British Journal of Pharmacology 135, no. 6 (2002): 1487–94. http://dx.doi.org/10.1038/sj.bjp.0704596.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

ONODERA, Sadayoshi, Masato TANAKA, Niro INABA, Takao SUZUKI, Masahiro SHIBATA, and Tetsuaki YAMAURA. "Effect of a novel antiulcer drug, lafutidine, on experimental chronic gastritis in rats." Folia Pharmacologica Japonica 109, no. 1 (1997): 31–40. http://dx.doi.org/10.1254/fpj.109.31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Onodera, Sadayoshi, Masato Tanaka, Misao Aoyama, et al. "Antiulcer Effect of Lafutidine on Indomethacin-Induced Gastric Antral Ulcers in Refed Rats." Japanese Journal of Pharmacology 80, no. 3 (1999): 229–36. http://dx.doi.org/10.1254/jjp.80.229.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Nishihara, Katsushi, Motoko Nakano, Yoshihisa Nozawa, et al. "Effect of lafutidine on CGRP release from cultured rat dorsal root ganglion cells." InflammoPharmacology 10, no. 4-6 (2002): 505–14. http://dx.doi.org/10.1163/156856002321544963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Malviya, Vedanshu, Mukund Tawar, Prashant Burange, and Ritu Bairagi. "Preparation and Characterization of Gastroreten-tive Sustained Release In-situ Gel of Lafutidine." International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN) 15, no. 6 (2022): 6216–28. http://dx.doi.org/10.37285/ijpsn.2022.15.6.4.

Full text

Abstract:

Background: The in-situ solutions, which float in the gastrointestinal region after gelation, is suited for long-term drug release. In this study, natural and synthetic polymers were used to try to build a Gastro-Retentive controlled release in-situ gel. To modulate the rate of drug distribution and increase bioavailability and stability, gastro-retentive controlled release in-situ gels were prepared.  Materials and Methods: For this project, 32 factorial designs were chosen. The two independent variables were sodium alginate (X1) and the ratio of HPMC K100M: Gellan Gum (X2) was preserve

APA, Harvard, Vancouver, ISO, and other styles

46

Mita, Ayako, Junko Yamana, and Morihiko Kodo. "A case of paclitaxel-induced peripheral neuropathy successfully treated with lafutidine and tocoferol nicotinate." Palliative Care Research 10, no. 3 (2015): 548–51. http://dx.doi.org/10.2512/jspm.10.548.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Poornima P, Poornima, and Sneh Priya. "Gastroretentive Floating Tablets Enclosing Nanosponge Loaded with Lafutidine for Gastric Ulcer: Formulation and Evaluation." Indian Journal of Pharmaceutical Education and Research 55, no. 1s (2021): s100—s111. http://dx.doi.org/10.5530/ijper.55.1s.41.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Pantwalawalkar, Jidnyasa, and Sopan Nangare. "Formulation of Silk Fibroin-based Single Polymeric Floating Microspheres for Sustained Release of Lafutidine." Indian Journal of Pharmaceutical Education and Research 56, no. 2 (2022): 396–404. http://dx.doi.org/10.5530/ijper.56.2.59.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Itoh, Hiroki, Takafumi Naito, and Masaharu Takeyama. "Lafutidine Changes Levels of Somatostatin, Calcitonin Gene-Related Peptide, and Secretin in Human Plasma." Biological & Pharmaceutical Bulletin 25, no. 3 (2002): 379–82. http://dx.doi.org/10.1248/bpb.25.379.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Vageesh, N. M., Ramya Sri Sura, K. Gulijar Begum, and B. Swathi. "Formulation Development and In vitro Evaluation of Floating Tablets of Lafutidine by Employing Effervescent Technology." Asian Journal of Pharmaceutical Research 7, no. 3 (2017): 189. http://dx.doi.org/10.5958/2231-5691.2017.00029.6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!